Healthcare -
Biotechnology - NASDAQ - US
$ 3.25
1.25 %
$ 278 M
Market Cap
-1.97
P/E
1. INTRINSIC VALUE
Balance Sheet
Atea Pharmaceuticals, Inc.
| Current Assets | 462 M |
| Cash & Short-Term Investments | 455 M |
| Receivables | 0 |
| Other Current Assets | 7.63 M |
| Non-Current Assets | 2.31 M |
| Long-Term Investments | 0 |
| PP&E | 2.12 M |
| Other Non-Current Assets | 197 K |
| Current Liabilities | 18.6 M |
| Accounts Payable | 4.46 M |
| Short-Term Debt | 800 K |
| Other Current Liabilities | 13.3 M |
| Non-Current Liabilities | 7.2 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 7.2 M |
EFFICIENCY
Earnings Waterfall
Atea Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 193 M |
| Operating Income | -193 M |
| Other Expenses | -24.6 M |
| Net Income | -168 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Atea Pharmaceuticals, Inc.
| Net Income | -168 M |
| Depreciation & Amortization | 416 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 51.8 M |
| Change in Working Capital | -7.48 M |
| Others | -19.5 M |
| Free Cash Flow | -135 M |
Wall Street Analysts Price Targets
Atea Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for AVIR of $6.88 , with forecasts ranging from
a
low of
$6.88 to a high of $6.88 .
AVIR Lowest Price Target
Wall Street Target
6.88 USD
111.69%
AVIR Average Price Target
Wall Street Target
6.88 USD
111.69%
AVIR Highest Price Target
Wall Street Target
6.88 USD
111.69%
4. DIVIDEND
ANALYSIS
AVIR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Atea Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.02 M USD 1
9-12 MONTHS
234 K USD 1
Bought
0 USD 0
0-3 MONTHS
163 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Sup porting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14 , 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. The Company's combination regimen of bemnifosbuvir (BEM), a nucleotide analog polymerase inhibitor, and ruzasvir (RZR), an NS5A inhibitor, is in Phase 3 development for the treatment of hepatitis C virus (HCV).
globenewswire.com
- 1 month ago
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Needed in Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 BOSTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented results from the full cohort of patients (n=275) enrolled in its Phase 2 study evaluating the once-daily combination of bemnifosbuvir (BEM), an oral nucleotide NS5B polymerase inhibitor, and ruzasvir (RZR), an oral NS5A inhibitor, for the treatment of hepatitis C virus (HCV).
globenewswire.com
- 1 month ago
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
Panel to Discuss Current Challenges Encountered by Patients with HCV , Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opinion leader (KOL) panel discussion on topics related to the treatment of HCV on Wednesday, May 14, 2025 at 10:00 AM ET. Atea also announced that it plans to issue a press release and report its first quarter 2025 financial results after the market closes on Monday, May 12, 2025.
globenewswire.com
- 2 months ago
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the full results from the Phase 2 clinical study of Atea's regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV) infection will be presented at the European Association for the Study of the Liver (EASL) Congress 2025. In addition, pharmacokinetic and safety results supporting the regimen's profile will also be presented. The EASL Congress 2025 will take place May 7-10 in Amsterdam, Netherlands.
globenewswire.com
- 2 months ago
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D.
globenewswire.com
- 2 months ago
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect
globenewswire.com
- 2 months ago
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination
States Change in Board Composition Sorely Needed Expresses Support for Radoff-JEC Group Nominees STAMFORD, Texas, March 31, 2025 (GLOBE NEWSWIRE) -- Driver Management Company LLC (“Driver”) today delivered a letter to Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) withdrawing a notice of nomination delivered to the Company on March 19, 2025 in order not to compete against the highly qualified candidates nominated for election to the Company's board of directors (the “Board”) by Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”).
globenewswire.com
- 3 months ago
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement:
globenewswire.com
- 3 months ago
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard H. Berman, James Flynn and Mr. Torok – for election to the Company's Board of Directors (the “Board”) at the 2025 Annual Meeting of Stockh.
businesswire.com
- 3 months ago
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirmed receipt of a notice from Bradley L. Radoff that he intends to nominate three director candidates to stand for election to the Atea Board of Directors at the Company's 2025 Annual Meeting of Stockholders.
globenewswire.com
- 3 months ago
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the poster presentation of bemnifosbuvir preclinical data at the 38th International Conference on Antiviral Research (ICAR) 2025 taking place March 17-21, 2025 in Las Vegas, Nevada.
globenewswire.com
- 3 months ago
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer & Executive Vice President, Legal Conference Call Participants Bella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 3 months ago
8. Profile
Summary
Atea Pharmaceuticals, Inc. AVIR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 278 M
Dividend Yield
0.00%
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Contact
125 Summer Street, Boston, MA, 02110
https://ateapharma.com
IPO
Date
Oct. 30, 2020
Employees
56
Officers
Mr. Wayne Foster CPA
Executive Vice President of Finance & Chief Accounting Officer
Mr. Xiao-Jian Zhou Ph.D.
Executive Vice President of Early Stage Development
Ms. Andrea J. Corcoran J.D.
Chief Financial Officer, Executive Vice President of Legal & Secretary
Mr. Adel Moussa Ph.D.
Executive Vice President of Chemistry
Mr. Keith Pietropaolo
Executive Vice President of Clinical Sciences & Project Management
Mr. John F. Vavricka
Chief Commercial Officer
Ms. Jonae R. Barnes
Senior Vice President of Investor Relations & Corporate Communications
Dr. Jean-Pierre Sommadossi Ph.D.
Founder, Chairman, Chief Executive Officer & President
Dr. Maria Arantxa Horga M.D.
Chief Medical Officer
Dr. Janet M. J. Hammond M.D., Ph.D.
Chief Development Officer